Braveheart Bio Data Goes Dark for 2024-Founded BRVE
Updated
Updated · CNN · Jul 31
Braveheart Bio Data Goes Dark for 2024-Founded BRVE
2 articles · Updated · CNN · Jul 31
Summary
BRVE's share price, price change and market open-close data were all listed as temporarily unavailable in the latest market snapshot.
Financial fields were also blanked out, with revenue, net income, earnings per share and market capitalization unavailable for Braveheart Bio.
The outage extended to forecasts and news feeds, leaving no 1-year price target, recent TipRanks articles or recent press releases on the page.
Braveheart Bio, founded on May 13, 2024 and based in San Francisco, is developing hypertrophic cardiomyopathy treatments led by cardiac myosin inhibitor BHB-1839.